Charles River Laboratories Intl. Inc vs State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF — how do they compare? Charles River Laboratories Intl. Inc trades at $301.79 (market cap $14.23B), while State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF trades at $30.77 (market cap $3.06B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 4.7× State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and State Street SPDR Bloomberg Invstmt Gr Fltg Rt ETF for 16 Days on average.
| CRL | FLRN | |
|---|---|---|
Market Cap | $14.23B | $3.06B |
Volume | 1,176,885 | 6,296,473 |
Sector | Health | Fixed Income |
52-Week High | $310.77 | $30.86 |
52-Week Low | $149.93 | $30.65 |
Typical Hold Time | 33 Days | 16 Days |
Enterprise Value | $17.06B | — |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $298, down 0.77% on the day, with strong analyst support showing 73% buy ratings and a $305.50 consensus price target. The stock maintains a bullish technical outlook with support at $292 and resistance at $301, while recent earnings have consistently beaten expectations despite negative net income margins. The company's 2026 Investor Day highlighted a strategic vision targeting 5-7% organic growth and $300 million in savings by 2030.
CRL presents a compelling growth story with solid operational cash flow and strategic initiatives, though investors face risks from negative profitability metrics and elevated valuation multiples. The stock's current position near analyst targets suggests limited upside without improved earnings execution, while ongoing margin pressures and debt levels require careful monitoring amid the company's transformation efforts.
FLRN (SPDR Bloomberg Investment Grade Floating Rate ETF) trades at $30.77 with minimal daily movement (+0.07%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. The ETF maintains consistent quarterly dividends of $0.11, with recent institutional buying interest from Concurrent Investment Advisors. Current market focus centers on floating rate bonds' performance amid rising interest rate expectations.
FLRN offers exposure to investment-grade floating rate bonds with near-zero duration, positioning it as a potential hedge against rate hikes. Key risks include concentrated financial sector exposure and sensitivity to credit spread changes. The ETF's structure provides income stability but faces headwinds from potential economic slowdowns affecting corporate bond markets.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →FLRN invests in U.S. dollar-denominated investment-grade floating rate notes with maturities under five years. It provides exposure to corporate and supranational debt whose interest payments adjust with market rates, helping to mitigate interest rate risk.
Read more on FLRN →